OTC
0.25USD
+0.02 (+9.53%)
We have scored 4 news catalysts on CytoDyn Inc. (CYDY) over the past 12 months. The biggest single-day move next to one of them came Oct 19, 2026, when CYDY closed +9.5%: “CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer”. Coverage across the window leans positive (average ticker sentiment +0.18). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
367.4M
P/E
—
EPS
—
Beta
1.24
52W range
0.18-0.4
Day range
0.23–0.29
Open
0.23
Prev close
0.23
Volume
2.3M
Avg volume
1.7M
Dividend
0.00
IPO
2006-12-13
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about CytoDyn Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for CYDY: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19). In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington.
